Compounds active against at least one kinase among EGFR and class III RTKs were evaluated for their cytotoxic properties against two different human cancer cell lines, namely non small cells A549 lung cancer cells (sensitive to EGFR inhibitors)46 and pancreatic BxPC3 adenocarcinoma (sensitive to both PDGFRβ and EGFR inhibitors)47, 48 cells. This evidence concerns the gene PDGFRB and adenocarcinoma.